Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055894 · ClinicalTrials.gov registry record · NA
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
A NA study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 7
- Study locations
NCT06055894: Recruiting NA study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06055894 is a NA study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 200 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06055894, a NA study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). The researchers will compare how the different dietary changes affect butyrate levels in participants' stool.
Primary Outcome
To evaluate the change in stool butyrate levels, which is defined as the average of -1 and 0 week samples. Patient stool will be assessed for butyrate levels in batches by gas chromatography mass spectrometry.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Omega-3
- DIETARY_SUPPLEMENT Curcumin
- DIETARY_SUPPLEMENT Probiotic
- OTHER Whole food, plant-based diet (WFPBD)
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT06055894 shows while recruiting
NCT06055894 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Omega-3 is the first listed.
NCT06055894 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06055894 about?
NCT06055894 is a clinical study titled "A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)". The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined...
What is the current status of trial NCT06055894?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2023-09-20. Estimated completion is 2026-09.
What conditions does trial NCT06055894 study?
This clinical trial studies the following conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering.
What interventions are being tested in trial NCT06055894?
The interventions under investigation include: Omega-3 (DIETARY_SUPPLEMENT), Curcumin (DIETARY_SUPPLEMENT), Probiotic (DIETARY_SUPPLEMENT), Whole food, plant-based diet (WFPBD) (OTHER).
Who is sponsoring clinical trial NCT06055894?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055894 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06055894's enrollment target sits among peer trials
200 110th of 438 higher than 324 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
-
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
RECRUITING · NA
-
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI